Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
18. Dezember 2019 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
23. April 2019 06:39 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 13/2019 ...
Orphazyme assumes sponsorship of Phase II/III sIBM trial
15. Dezember 2017 09:20 ET
|
ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...